Skip to content

Clinical trials

Dyspareunia trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Dyspareunia Clear all

150 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20022
20043
20051
20063
20073
20082
20091
20105
20112
20123
20136
20147
20151
20169
201710
201815
20196
20205
202110
202211
20235
202412
202514
202611

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed84
Recruiting25
Unknown status20
Not yet recruiting8
Terminated5
Withdrawn3
Active, not recruiting3
Enrolling by invitation1
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Kissei Pharmaceutical Co., Ltd.4
Abbott3
BC Women's Hospital & Health Centre3
Kanuni Sultan Suleyman Training and Research Hospital3
Medstar Health Research Institute3
Ohio State University Comprehensive Cancer Center3
Riphah International University3
Cairo University2
Corewell Health East2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Dyspareunia150
Endometriosis31
Dysmenorrhea24
Sexual Dysfunction, Physiological22
Pelvic Pain20
Vulvodynia17
Pain14
Breast Neoplasms10
Vaginismus9
Constipation7

Trials

Showing 1 to 25 of 150. Each trial links to its page on Pharma Observatory.

50 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.